Published by Josh White on 4th July 2017
(ShareCast News) - Biopsy company ANGLE announced positive headline results from 400 patient pelvic mass studies in the US and Europe on Tuesday, reportedly demonstrating the potential for a 'Parsortix'-based blood test to outperform current tests in discriminating between benign and malignant pelvic masses.